for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agile Therapeutics Inc

AGRX.OQ

Latest Trade

1.41USD

Change

-0.04(-2.76%)

Volume

206,712

Today's Range

1.40

 - 

1.46

52 Week Range

1.28

 - 

3.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.45
Open
1.45
Volume
206,712
3M AVG Volume
22.71
Today's High
1.46
Today's Low
1.40
52 Week High
3.88
52 Week Low
1.28
Shares Out (MIL)
88.26
Market Cap (MIL)
124.45
Forward P/E
-1.99
Dividend (Yield %)
--

Next Event

Q2 2021 Agile Therapeutics Inc Earnings Release

Latest Developments

More

Agile Therapeutics Q1 Net Loss $0.20 Per Share

Agile Therapeutics Reports Q4 Loss Per Share Of $0.20

Agile Therapeutics Reports Q3 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Agile Therapeutics Inc

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Industry

Business Services

Contact Info

101 Poor Farm Rd

PRINCETON, NJ

08540-1941

United States

+1.609.6831880

https://www.agiletherapeutics.com/

Executive Leadership

Alfred Altomari

Chairman of the Board, Chief Executive Officer

Dennis P. Reilly

Chief Financial Officer, Senior Vice President

Geoffrey P. Gilmore

Senior Vice President, General Counsel, Corporate Secretary

Robert G. Conway

Senior Vice President and Chief Supply Chain Officer

Paul Korner

Senior Vice President, Chief Medical Officer

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.580

2019

-0.380

2020

-0.610

2021(E)

-0.708
Price To Earnings (TTM)
--
Price To Sales (TTM)
143.88
Price To Book (MRQ)
3.55
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
44.61
LT Debt To Equity (MRQ)
44.61
Return on Investment (TTM)
-77.95
Return on Equity (TTM)
-72.58

Latest News

Latest News

BRIEF-Agile Therapeutics - Set Up Wholesale Acquisition Cost Of $159.75 For Treatment Cycle Of Twirla Transdermal System

* AGILE THERAPEUTICS - ON JUNE 26, CO ESTABLISHED A WHOLESALE ACQUISITION COST OF $159.75 FOR A TREATMENT CYCLE OF ITS TWIRLA TRANSDERMAL SYSTEM.

BRIEF-Agile Therapeutics To Join Russell 3000 And 2000 Indexes

* AGILE THERAPEUTICS TO JOIN RUSSELL 3000® AND 2000® INDEXES Source text for Eikon: Further company coverage:

BRIEF-Agile Therapeutics Reports First Quarter 2020 Financial Results

* AGILE THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Agile Therapeutics Posts Quarterly Loss Per Share Of $0.10

* AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Agile Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock

* AGILE THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

FDA delays review of Agile's birth control patch by 3 months; shares slide

The U.S. Food and Drug Administration on Thursday delayed its review of Agile Therapeutics Inc's hormonal contraceptive patch by three months, sending its shares down 35% after the bell.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up